Nurix Therapeutics 

Yahoo Finance • last month

Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million

On February 17, 2026, Redmile Group disclosed a buy of 4,415,514 Nurix Therapeutics(NASDAQ:NRIX) shares, an estimated $63.43 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Commissio... Full story

Yahoo Finance • last month

Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120%

On February 17, 2026, Redmile Group disclosed a buy of 695,000 shares of Immunome(NASDAQ:IMNM), an estimated $12.20 million trade based on quarterly average pricing. What happened According to a February 17, 2026, SEC filing, Redmile Gro... Full story

Yahoo Finance • last month

Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year

Redmile Group disclosed a significant reduction in its Zymeworks(NASDAQ:ZYME) position in a February 17, 2026, SEC filing, selling an estimated $70.10 million in shares based on quarterly average pricing. What happened According to a Feb... Full story

Yahoo Finance • last month

Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025

Redmile Group reported a purchase of 16,317 shares of Krystal Biotech(NASDAQ:KRYS) in its February 17, 2026, SEC filing, with the estimated transaction value at $3.43 million based on quarterly average pricing. What happened According to... Full story

Yahoo Finance • last month

Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26%

Redmile Group disclosed a buy of 1,316,390 shares of Scholar Rock Holding Corporation(NASDAQ:SRRK) in a February 17, 2026, SEC filing, with the estimated transaction value at $49.37 million based on quarterly average pricing. What happene... Full story

Yahoo Finance • 2 months ago

Stifel Raised Nurix Therapeutics, Inc. (NRIX) Price Target to $35 and Maintains Buy Ahead of 2026 Catalysts

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Nurix Therapeutics, Inc. is placed second on our list. TheFly reported on January 29 that Stifel raised the price target on NRIX to $35 from $33 and maintaine... Full story

Yahoo Finance • 3 months ago

Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge

VANCOUVER, British Columbia, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Equity InsiderNews Commentary – The U.S. oncology market is projected to surge from $81 billion in 2025 to $212 billion by 2034[1], driven by a fundamental shift in how physi... Full story

Yahoo Finance • 3 months ago

Wells Fargo Reaffirms a Buy Rating on Nurix Therapeutics (NRIX), Sets a $30 PT

Nurix Therapeutics, Inc. (NASDAQ:NRIX) is one of the best small cap stocks to buy with huge upside potential. On December 16, Wells Fargo analyst Derek Archila reaffirmed a Buy rating on Nurix Therapeutics, Inc. (NASDAQ:NRIX) with a $30 pr... Full story

Yahoo Finance • 4 months ago

Cathie Wood tilts toward Robinhood, Bitcoin ETFs, trims Tesla, Iridium

[Bitcoin 2022 Conference Draws Cryptocurrency Industry Professionals And Investors To Miami] Marco Bello Cathie Wood’s ARK Investment Management chopped its holdings in EV maker Tesla (TSLA [https://seekingalpha.com/symbol/TSLA]) and sate... Full story

Yahoo Finance • 4 months ago

Kymera Rockets, Pulling Nurix Higher. Does It Have The Next Dupixent?

Kymera Therapeutics could have the next Dupixent, analysts said Monday, as shares skyrocketed on promising test results in eczema. Continue Reading... Full story

Yahoo Finance • 4 months ago

Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition

Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression free survival (PFS) of 22.1 months across all doses tested Emerging data from randomized Phase 1b cohorts poin... Full story

Yahoo Finance • 4 months ago

Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in... Full story

Yahoo Finance • 5 months ago

Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors

SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in... Full story

Yahoo Finance • 5 months ago

Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in... Full story

Yahoo Finance • 5 months ago

Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock

SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines i... Full story

Yahoo Finance • 5 months ago

Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock

SAN FRANCISCO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in... Full story

Yahoo Finance • 5 months ago

Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia

600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Phase 2 DAYBreak trial initiated for potential Accelerated Approval New pr... Full story

Yahoo Finance • 5 months ago

Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress

NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint mechanism distinct from PD-1/PD-L1 therapies NX-1607 demonstrated evidence of monotherapy anti-tu... Full story

Yahoo Finance • 6 months ago

Stocks Climb as Dovish Fed Comments Knock Bond Yields Lower

The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) today is up +0.32%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/futures/q... Full story

Yahoo Finance • 6 months ago

Nurix Therapeutics GAAP EPS of -$1.03 misses by $0.11, revenue of $7.9M misses by $4.33M

* Nurix Therapeutics press release [https://seekingalpha.com/pr/20261446-nurix-therapeutics-reports-third-quarter-2025-financial-results-and-provides-a-corporate] (NASDAQ:NRIX [https://seekingalpha.com/symbol/NRIX]): Q3 GAAP EPS of -$1.0... Full story